Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs OneSpan Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while OneSpan Inc trades at $17.52 (market cap $648.23M). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 13.7× OneSpan Inc's market cap, and OneSpan Inc pays a 2.96% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and OneSpan Inc for 18 Days on average.
| KYMR | OSPN | |
|---|---|---|
Market Cap | $8.88B | $648.23M |
Volume | 1,028,790 | 466,478 |
Sector | Health | Technology |
52-Week High | $127.31 | $18.42 |
52-Week Low | $55.80 | $10.15 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $8.27B | $617.31M |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
OneSpan (OSPN) trades at $18.20, up 1.96% with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 27.76% net margins and consistent earnings beats, though revenue growth remains modest. Analyst sentiment is positive with 67% buy ratings, while recent news highlights investor interest and product innovation with the DigipassONE launch.
The stock presents value appeal with a P/E under 10 and robust cash generation, but faces execution risks amid competitive pressures and declining net cash flow. Upside potential hinges on subscription revenue growth offsetting hardware declines, with investor focus on Q3 earnings delivery against expectations of $0.236 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
